Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 17, 2026.

Parkinson’s disease: animal models and dopaminergic cell vulnerability

Javier Blesa, Serge Przedborski

Frontiers in Neuroanatomy · 2014 · Review

doi:10.3389/fnana.2014.00155

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder that affects about 1.5% of the global population over 65 years of age. A hallmark feature of PD is the degeneration of the dopamine (DA) neurons in the substantia nigra pars compacta (SNc) and the consequent striatal DA deficiency. Yet, the pathogenesis of PD remains unclear. Despite tremendous growth in recent years in our knowledge of the molecular basis of PD and the molecular pathways of cell death, important questions remain, such as: (1) why are SNc cells especially vulnerable; (2) which mechanisms underlie progressive SNc cell loss; and (3) what do Lewy bodies or α-synuclein reveal about disease progression. Understanding the variable vulnerability of the dopaminergic neurons from the midbrain and the mechanisms whereby pathology becomes widespread are some of the primary objectives of research in PD. Animal models are the best tools to study the pathogenesis of PD. The identification of PD-related genes has led to the development of genetic PD models as an alternative to the classical toxin-based ones, but does the dopaminergic neuronal loss in actual animal models adequately recapitulate that of the human disease? The selection of a particular animal model is very important for the specific goals of the different experiments. In this review, we provide a summary of our current knowledge about the different in vivo models of PD that are used in relation to the vulnerability of the dopaminergic neurons in the midbrain in the pathogenesis of PD.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

INTRODUCTION

Parkinson’s disease (PD) is a common neurodegenerative disorder whose prevalence increases with age. The cardinal features of PD include tremor, rigidity and slowness of movements, albeit non-motor manifestations such as depression and sleep disturbances are increasingly recognized in these patients. Over the past decade, more attention has also been paid to the broader nature of the neurodegenerative changes in the brains of PD patients. Indeed, for many years, the neuropathological focus has been on the striking neurodegeneration of the nigrostriatal dopaminergic pathway, however, nowadays, disturbances of the serotonergic, noradrenergic, glutamatergic, GABAergic, and cholinergic systems as well as alterations in neural circuits are now being intensively investigated from the angle of the pathophysiology of PD, with the underlying expectation of acquiring a better understanding of the neurobiology of this disabling disorder and of identifying new targets for therapeutic purposes. From a molecular biology point of view, the accepted opinion that the PD neurodegenerative process affects much more than the dopaminergic neurons of the substantia nigra pars compacta (SNc), has triggered a set of fascinating questions such as: are dopaminergic and non-dopaminergic neurons in PD dying by the same pathogenic mechanisms; and, given the fact that within a given subtype of neurons, not all die to the same extent nor at the same rate [e.g., dopaminergic neurons in the SNc vs. ventral tegmental area (VTA)], what are the molecular determinants of susceptibly/and resistance to disease?

To gain insights into these types of critical questions, a brief review of the literature demonstrates that the enthusiasm for experimental models of PD, both in vitro and in vivo, has greatly increased, in part, thanks to new strategies for producing sophisticated models, such as the temporal- and/or cell-specific expression of mutated genes in mice, human pluripotent cells coaxed into a specific type of neurons, and a host of invertebrate organisms like Drosophila, Caenorhabditis elegans, or Medaka fish. Thus far, however, all of these experimental models continue to be categorized into two main flavors: toxic and genetic (and sometimes, both approaches are combined). But, more importantly, none of the currently available models phenocopy PD, mainly because they lack some specific neuropathological and/or behavioral feature of PD. Some PD experts see this as fatal flaws, while others tend to ignore the shortcomings. It has always been our personal view that models are just models and, as such, given the large collection of models the field of PD possesses, the prerequisite resides in not using just any model but in selecting the optimal in vitro or in vivo model whose strengths are appropriate for investigating the question being asked and whose weaknesses will not invalidate the interpretation of an experiment.

Based on our above premise, herein, we discuss the experimental models of PD, with a deliberate emphasis on in vivo mammalian models induced by reproducible means. Over the years, a constellation of uncommon strategies and organisms have been used to produce models of PD. However, in this review, we have decided not to discuss these cases, because we have limited space and because we are missing sufficient independent information to assessment the reproducibility and reliability of these models, which, to us, is critical for distinguishing between interesting “case reports” and useful tools to model human diseases.

TOXIN MODELS

A number of pharmacological and toxic agents including reserpine, haloperidol, and inflammogens like lipopolysaccharide have been used over the years to model PD, although the two most widely used are still the classical 6-OHDA in rats and MPTP in mice and monkeys. Although the neurotoxic models appear to be the best ones for testing degeneration of the nigrostriatal pathway, some striking departures from PD need to be mentioned: the degeneration of dopaminergic neurons progress rapidly, i.e., days not years, lesions are primarily if not exclusively dopaminergic, and animals lack the typical PD proteinaceous inclusions called Lewy bodies (LBs). In addition, behavioral abnormalities in these animal models are also a challenging question (see below; Table 1).

MPTP

MPTP is the tool of choice for investigations into the mechanisms involved in the death of DA neurons in PD. MPTP has been shown to be toxic in a large range of species. The most popular species, besides primates, is the mouse, as rats were found to be resistant to this toxin. A number of intoxication regimens or administration methods have been used over the years in mouse and in primates. In both species, MPTP primarily causes damage to the nigrostriatal DA pathway with a profound loss of DA in the striatum and SNc.

This specific and reproducible neurotoxic effect on the nigrostriatal system is the strength of this model. Neuropathological data show that MPTP administration causes damage to the nigrostriatal DA pathway that is identical to that seen in PD, yet there is a resemblance that goes beyond the loss of SNc DA neurons. Like in PD, MPTP causes greater loss of DA neurons in SNc than in VTA or retrorubral field and, at least in monkeys treated with low doses of MPTP, greater degeneration of DA nerve terminals in the putamen than in the caudate nucleus.

A often raised weakness with this model is the lack of LB. Although no LBs have been observed in these models so far, a few reports have investigated the expression, regulation or pattern of α-syn after MPTP exposure. Only, in MPTP-injected monkeys, have intraneuronal inclusions, reminiscent of LBs, been described. Behavior is also an issue, and except for the monkeys, features reminiscent of PD are lacking especially in mice. Yet, using a battery of tests, some motor alterations in mice with profound dopaminergic deficit may be detected.

6-OHDA

Like MPTP, 6-OHDA is a selective catecholaminergic neurotoxin that is used, mainly, to generate lesions in the nigrostriatal DA neurons in rats. Since 6-OHDA cannot cross the blood-brain barrier, systemic administration fails to induce parkinsonism. So, this induction model requires that 6-OHDA be injected (typically as a unilateral injection) into the SNc, medial forebrain bundle or striatum. Intraventricular administration has also been achieved. The effects resemble those in the acute MPTP model, causing neuronal death over a brief time course (12 h to 2–3 days). The intrastriatal injection of 6-OHDA causes progressive retrograde neuronal degeneration in the SNc and VTA. The pattern of DA loss in animals bearing a full lesion (>90%) again mirrors seen that in PD, with the SNc showing more cells loss compared to the VTA. As in PD, DA neurons are killed, and the non-DA neurons are preserved. However, like in the MPTP model, 6-OHDA does not produce LB-like inclusions in the nigrostriatal pathway. Traditionally, behavioral assessments of motor impairments in the unilateral 6-OHDA model are done by drug-induced rotation tests. However, drug-free sensorimotor behavioral tests have been developed in both rat and mice that may be helpful for the preclinical testing of new symptomatic strategies.

ROTENONE

Chronic systemic exposure to rotenone in rats causes many features of PD, including nigrostriatal DA degeneration. The rotenone-administered animal model also reproduces all of the behavioral features reminiscent of human PD. Importantly, many of the degenerating neurons have intracellular inclusions that resemble LB morphologically. These inclusions show immunoreactivity for α-syn and ubiquitin as did the original LB. Usually, rotenone is administered by daily intraperitoneal injection, intravenously or subcutaneously. Recently, rotenone has been tested in mice through chronic intragastric administration, or as a stereotaxic injection or infusion directly in the brain recapitulating the slow and specific loss of DA neurons. However, administration of rotenone in rats causes high mortality and, somehow, is difficult to replicate.

PARAQUAT/MANEB

Although the idea that the herbicide paraquat (N,N′-dimethyl-4-4-4′-bypiridinium), may cause parkinsonism in humans has attracted some interest, at this time, as pointed out by Berry and collaborators, epidemiological and clinical evidence that paraquat may cause PD is inconclusive. And, the same view seems to apply to the fungicide maneb (manganese ethylenebisdithiocarbamate; ). Moreover, effects of this compound in the nigrostriatal DA system is somewhat ambiguous. Regarding animal models, some researchers report that, following the systemic application of paraquat, mice exhibit reduced motor activity and a dose-dependent loss of striatal tyrosine hydroxylase (TH) fibers and SNc neurons with relative sparing of the VTA. Like rotenone, paraquat may be useful in the laboratory because of its presumed ability to induce LB in DA neurons. Maneb has been shown to decrease locomotor activity and produce SNc neurons loss and potentiate both the MPTP and the paraquat effects. However, as with rotenone, this model shows contradictory results, variable cell death and loss of striatal DA content.

AMPHETAMINE-TYPE PSYCHOSTIMULANTS

Some amphetamine derivatives such as methamphetamine (METH) and 3,4-methylenedioxymethamphetamine (MDMA) also have neurotoxic effects on the nervous system causing not only functional deficits but also structural alterations. The first study to show DA depletion in rats following repeated, high-dose exposure to METH was conducted by. and showed that high-dose treatment with METH in mice resulted in a loss of DA cells in the SNc. Since then, several studies have reported selective DA or serotonergic nerve terminal as well as SNc neuronal loss in rodents, primates or even guinea pig following the administration of very high doses of METH.

3,4-Methylenedioxymethamphetamine can also elicit significant neurobehavioral adverse effects. Although MDMA toxicity mainly affects the serotonergic system, DA system can also be affected to a lesser extent. In mice, repeated administration of MDMA produces degeneration of DA terminals in the striatum and TH+ neuronal loss in the SNc.

Exposure to low concentrations of METH results in a decrease of the vulnerability of the SNc DA cells to toxins like 6-OHDA or MPTP. On the other hand, chronic exposure to MDMA of adolescent mice exacerbates DA neurotoxicity elicited by MPTP in the SNc and striatum at adulthood. Hence, a METH or MDMA-treated animal model could be useful to study the mechanisms of DA neurodegeneration.

GENETIC MODELS

Genetic models may better simulate the mechanisms underlying the genetic forms of PD, even though their pathological and behavioral phenotypes are often quite different from the human condition. A number of cellular and molecular dysfunctions have been shown to result from these gene defects like fragmented and dysfunctional mitochondria, altered mitophagy, ubiquitin–proteasome dysfunction, and altered reactive oxygen species production and calcium handling. Some studies have reported alterations in motor function and behavior in these mice, and sensitivities to complex I toxins, like MPTP, different from wild type (WT) mice although this latter finding is not always consistent. However, almost all of the studies evaluating the integrity of the nigrostriatal DA system in these genetic models failed to find significant loss of DA neurons. Thus, recapitulation of the genetic alterations in mice is insufficient to reproduce the final neuropathological feature of PD. Below, we describe transgenic mice or rat models which recapitulate the most known mutations observed in familial PD patients (Table 1).

α-SYNUCLEIN

α-syn was the first gene linked to a dominant-type, familial PD, called Park1, and is the main component of LB which are observed in the PD brain. Three missense mutations of α-syn, encoding the substitutions A30P, A53T, and E46K, have been identified in familial PD so far. Furthermore, the duplication or triplication of α-syn is sufficient to cause PD, suggesting that the level of α-syn expression is a critical determinant of PD progression.

To date, various α-syn transgenic mice have been developed. Although, in some of these mice, decreased striatal levels of TH or DA and behavioral impairments indicate that the accumulation of α-syn can significantly alter the functioning of DA neurons, no significant nigrostriatal degeneration has been found in most of them. The models of α-syn overexpression in mice recapitulate the neurodegeneration, depending primarily on the promoter used to drive the expression of the transgene, whether the transgene codes for the WT or the mutated protein, and the level of expression.

Although a lot of behavioral alterations have been described in both the A30P and A53T mice, the mouse prion protein promoter failed to reproduce the cell loss in the SNc or locus coeruleus (LC;;; ). The same phenotype was found with the hamster prion promoter. Mice based on the PDGF-β promoter showed loss of terminals and DA in the striatum but no TH+ cell loss. The TH promoter led to TH+ cell loss only in a few studies but did not replicate the α-syn neuropathology as did the Thy-1 promoter. However, the use of the murine Thy-1 promoter often causes loss of DA levels in the striatum but only moderate nigral DA cell loss in the SNc, with α-syn pathology. A new line of tetracycline-regulated inducible transgenic mice that overexpressed α-syn A53T under control of the promoter of Pitx3 in the DA neurons developed profound motor disabilities and robust midbrain neurons neurodegeneration, profound decrease of DA release, the fragmentation of Golgi apparatus, and the impairments of autophagy/lysosome degradation pathways. generated BAC transgenic mice (SNCA-OVX) that express WT human α-syn and which display an age-dependent loss of SNc DA neurons preceded by early deficits in DA release from terminals in the dorsal striatum, protein aggregation and reduced firing of SNc DA neurons. Regarding the transgene expressed, the A53T seems to be more effective than the A30P, in general.

Several viral vectors, primarily lentiviruses and adeno-associated viruses (AAVs), have been used to drive exogenous α-syn. Rats are usually used for these studies because viral vector delivery requires stereotactic injections within or near the site of the neuronal cell bodies in the SNc. In contrast to all of the α-syn transgenic mice, viral vector-mediated α-syn models display α-syn pathology and clear dopaminergic neurodegeneration. The injection of human WT or A53T mutant α-syn by AAVs into the SNc neurons of rats induces a progressive, age-dependent loss of DA neurons, motor impairment, and α-syn cytoplasmic inclusions. This cell loss was preceded by degenerative changes in striatal axons and terminals, and the presence of α-syn positive inclusions in axons and dendrites. These results have been replicated in mice. Although these models still suffer from a certain degree of variability, they can be of great value for further development and testing of neuroprotective strategies.

Recently, several studies have demonstrated that α-syn may be transmissible from cell to cell. In WT mice, a single intrastriatal inoculation of synthetic α-syn fibrils or pathological α-syn purified from postmortem PD brains led to the cell-to-cell transmission of pathologic α-syn and LB pathology in anatomically interconnected regions and was accompanied by a progressive loss of dopaminergic neurons in the SNc and reduced DA levels in the striatum, culminating in motor deficits. Moreover, the hind limb intramuscular injection of α-syn can induce pathology in the central nervous system in transgenic mouse models.

LRKK2

Mutations in LRRK2 are known to cause a late-onset autosomal dominant inherited form of PD. Several mutations have been identified in LRRK2, the most frequent being the G2019S mutation, a point mutation in the kinase domain, whereas R1441C, a mutation in the guanosine triphosphatase domain, is the second most common. Overall, LRRK2 mice models display mild or not functional disruption of the nigrostriatal DA neurons of the SNc.

LRRK2 KO mice are viable and have an intact nigrostriatal DA pathway up to 2 years of age. Neuropathological features associated with neurodegeneration or altered neuronal structure were absent, but α-syn or ubiquitin accumulation has been reported in these mice. To date, two LRRK2 KO rat models have been developed, although the consequences of LRRK2 deficiency in the brain are still unknown.

Both G2019S and R1441C LRRK2 KI mice are viable, fertile, and appear grossly normal. This mutation had no impact on DA neuron number or morphology in the SNc, or on noradrenergic neurons in the LC. Striatal DA levels and DA turnover are also normal in these mice.

Overexpression of G2019S LRRK2 leads to a mild progressive and selective degeneration of SNc DA neurons (20%) up to 2 years of age. Furthermore, no alteration in striatal DA levels or locomotor activity could be detected in older G2019S LRRK2 mice. Also, generated transgenic mice constitutively expressing V5-tagged human I2020T LRRK2 from a CMV promoter with no influence on SNc DA neuronal number or striatal DA fiber density. developed a transgenic rat model expressing G2019S LRRK2. Despite a mild behavioral alteration, LRRK2 expression had no effect on the number of DA neurons or on striatal DA content. Recently, conditional expression of R1441C LRRK2 in midbrain dopaminergic neurons of mice results in nuclear abnormalities but, without neurodegeneration.

Additional LRRK2 BAC transgenic mouse models have also been developed. These mice displayed age-dependent and progressive motor deficits at 10–12 months of age, accompanied by a mild reduction of striatal DA release. Adult neurogenesis and neurite outgrowth are impaired. No DA neurons loss or degeneration of striatal nerve terminals where observed in mice at 9–10 months of age.

Regarding the viral vector-based models, developed a herpes simplex virus (HSV) amplicon-based mouse model of G2019S LRRK2-induced DA neurotoxicity. The nigrostriatal expression of WT LRRK2 induced modest nigral DA neurodegeneration (10–20%), whereas expression of the kinase-hyperactive G2019S LRRK2 resulted in a 50% neuronal loss in the ipsilateral SNc associated with reduced striatal DA fiber density at 3 weeks post-injection. In another study, a model based on the unilateral injection of recombinant, second-generation human serotype 5 adenoviral (rAd) vectors expressing FLAG-tagged human WT or G2019S LRRK2 driven by a neuronal-specific human synapsin-1 promoter in rats induced the progressive loss (20%) of DA neurons in the ipsilateral SNc over 42 days, but with no reduction of striatal DA fiber density.

PINK1

Mutations in the gene PINK1 cause another form of PD called PARK6. PINK1 KO mice have an age-dependent, moderate reduction in striatal DA levels accompanied by low locomotor activity, but do not exhibit major abnormalities in the DA neurons or striatal DA levels. These mice showed no LB formation or nigrostriatal degeneration for up to 18 months of age. However, in PINK1 KO mice, overexpression of α-syn in the SNc resulted in enhanced dopaminergic neuron degeneration as well as significantly higher levels of α-syn phosphorylation at serine 129 at 4 weeks post-injection. Recently, a PINK1 null mouse with an exon 4–5 deletion displayed a progressive loss of DA in the striatum, but there was no degeneration in the SNc. The phenotypes of these mice are very similar to those of Parkin KO and DJ-1 KO mice.

PARKIN

Parkin is an E3 ubiquitin ligase that functions in the ubiquitin–proteasome system. Mutations in parkin are a cause of familial PD and are also seen in some young-onset sporadic PD cases. Several parkin KO mice have been generated, typically produced by deletion at exon 3, exon 7, or exon 2 in the PRKN gene. However, they show no substantial DA-related behavioral abnormalities. Some of these KO mice exhibit slightly impaired DA release and reduced norepinephrine levels in the olfactory bulb and spinal cord with an abnormal nigrostriatal region but without loss of SNc neurons.

Only the Parkin-Q311X-DAT-BAC mice exhibit multiple late onsets and progressive hypokinetic motor deficits, age-dependent DA neuron degeneration in the SNc and a significant reduction in striatal DA and dopaminergic terminals in the striatum. Recently, overexpression of T240R-parkin and of human WT parkin induced progressive and dose-dependent DA cell death in rats.

DJ-1

DJ-1 mutations are linked to an autosomal recessive, early onset PD. KO models of DJ-1 mice with a targeted deletion of exon 2 or insertion of a premature stop codon in exon 1 show decreased locomotor activity, a reduction in the release of evoked DA in the striatum but no loss of SNc DA neurons and no change of the DA levels. However, one line of DJ-1 KO mice shows loss of DA neurons in the VTA.

Interestingly, a recently described DJ-1 KO mouse, backcrossed on a C57/BL6 background, displayed a dramatic early onset unilateral loss of DA neurons in the SNc, progressing to bilateral degeneration of the nigrostriatal axis, with aging. In addition, these mice exhibit age-dependent bilateral degeneration in the LC and display, with aging, a mild motor behavioral deficit at specific time points. Therefore, if confirmed, this new mouse model would provide a tool to study the preclinical aspects of PD.

ATP13A2

Mutations in ATP13A2 (PARK9), encoding a lysosomal P-type ATPase, are associated with both Kufor–Rakeb syndrome (KRS) and neuronal ceroid lipofuscinosis. KRS has recently been classified as a rare genetic form of PD. Despite the accumulation of lipofuscin deposits in the SNc and late-onset sensorimotor deficits, there was no change in the number of DA neurons in the SNc or in striatal DA levels in aged Atp13a2 KO mice.

OTHER MODELS

Inactivation of multiple PD genes has been shown to be insufficient to cause significant nigral degeneration within the lifespan of mice. Triple KO mice lacking Parkin, DJ-1, or PINK1 have normal morphology and normal numbers of dopaminergic and noradrenergic neurons in the SNc and LC. Also, levels of striatal DA in these triple KO mice were normal at 16 months, but increased at 24 months of age.

Sonic hedgehog (SHH), nuclear receptor related protein-1 (Nurr1), pituitary homeobox3 (Pitx3), and engrailed 1 (EN1) are transcription factors important to the development and maintenance of the nigro-striatal system. Both SHH and Nurr1 KO mice show a progressive loss of DA neurons without LB formation. Also, Pitx3 gene mutations cause a complete loss of SNc and VTA DA neurons and altered locomotor activity in mice. Recently, engrailed 1 heterozygous mice (En1+/–) showed a significant and progressive retrograde degeneration of SNc neurons and dystrophic and swollen striatal TH+ terminals. c-Rel (a subunit of the NFκB complex) KO mice also develop a PD-like neuropathology on aging. At 18 months of age, c-rel (–/–) mice exhibit a significant loss of DA neurons in the SNc, loss of dopaminergic terminals and a significant reduction of DA and HVA levels in the striatum. In addition, these mice show age-dependent deficits in locomotor activity and a marked immunoreactivity for fibrillary α-syn in the SNc.

Conditional disruption of the gene for mitochondrial transcription factor A in DA neurons (MitoPark) results in a parkinsonism phenotype in mice that includes an adult-onset, slowly progressive impairment of motor function, DA neuron death, degeneration of nigrostriatal pathways and intraneuronal inclusions. Also, cell-specific deletion of the essential autophagy gene Atg7 in midbrain DA neurons causes DA neuron loss in the SNc at 9 months, accompanied by late-onset locomotor deficits. Atg7-deficient DA neurons in the midbrain also exhibit early dendritic and axonal dystrophy, reduced striatal DA content, and the formation of somatic and dendritic ubiquitinated inclusions.

Recently, it has been suggested that a vesicular monoamine tranporter (VMAT2) defect may be an early abnormality promoting mechanisms leading to nigrostriatal DA neuron death in PD. VMAT2-deficient mice display a progressive loss of nigral DA and LC cells, loss of striatal DA and α-syn accumulation. Neuroprotection from MPTP toxicity in VMAT2-overexpressors and enhanced MPTP toxicity in VMAT2-KO mice suggest that interventions aimed at enhancing vesicular capacity may be of therapeutic benefit in PD.

CONCLUDING REMARKS

Despite the significant contribution of all of these animal models to our understanding of PD, none of these models reproduce the human condition. If we consider toxic models, significant nigrostriatal degeneration is generally obtained with some motor deficits (particularly in MPTP-treated monkeys). Although no consistent LB-like formation is detected, this issue in the study of PD pathogenesis remains to be demonstrated. On the other hand, although transgenic models offer insights into the causes of PD pathogenesis or LB-like formation, the absence of consistent neuronal loss in the SNc remains a major limitation for these models. Another troubling observation in genetic models is the often inconsistent phenotypes among the lines with the same mutations. Whether or not this is related to an artifact of insertion of the transgene or to the actual genetic background, it would be advisable to test these in more than one line.

In addition to the classical motor abnormalities observed in PD, animal models are increasingly used to study non-motor symptoms (sleep disturbances, neuropsychiatric and cognitive deficits;; ). Both toxin-based and genetic models are suitable for studying these non-motor symptoms that are increasingly recognized as relevant in disease-state. Toxins-based models have been mostly used to seek the mechanisms involved in levodopa induced dyskinesias (LID) thus far. However, recently viral vector-mediated silencing of TH was used to induce striatal DA depletion without affecting the anatomical integrity of the presynaptic terminals and study LID. And more recently, for the first time, a genetic mouse model overexpressing A53T α-syn in nigrostriatal and corticostriatal projection neurons shows involuntary movements and increased post-synaptic sensitivity to apomorphine. It seems unlikely that a single model can fully recapitulate the complexity of the human disease. Future models should involve a combination of neurotoxin and genetic animal models in order to study the progressive neurodegeneration associated with PD. Understanding the mechanisms responsible for this progressive and intrinsic SNc neuronal loss is completely necessary at this point.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 203

  1. 1.
    Increased Mitochondrial Calcium Sensitivity and Abnormal Expression of Innate Immunity Genes Precede Dopaminergic Defects in Pink1-Deficient Mice · 2011
    No notice
  2. 2.

    Alam M. Mayerhofer A. Schmidt W. J. (2004 ). The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA. Behav. Brain Res. 151 117–124

    Not in our library10.1016/j.bbr.2003.08.014

  3. 3.

    Andres-Mateos E. Mejias R. Sasaki M. Li X. Lin B. M. Biskup S. (2009 ). Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). J. Neurosci. 29 15846–15850

    Not in our library10.1523/jneurosci.4357-09.2009

  4. 4.

    Andres-Mateos E. Perier C. Zhang L. Blanchard-Fillion B. Greco T. M. Thomas B. (2007 ). DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc. Natl. Acad. Sci. U.S.A. 104 14807–14812

    Not in our library10.1073/pnas.0703219104

  5. 5.

    Baiguera C. Alghisi M. Pinna A. Bellucci A. De Luca M. A. Frau L. (2012 ). Late-onset Parkinsonism in NFκB/c-Rel-deficient mice. Brain 135 2750–2765

    Not in our library10.1093/brain/aws193

  6. 6.
    Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs · 2013
    No notice
  7. 7.

    Bastías-Candia S. Di Benedetto M. D’Addario C. Candeletti S. Romualdi P. (2013 ). Combined exposure to agriculture pesticides, paraquat and maneb, induces alterations in the N/OFQ-NOPr and PDYN/KOPr systems in rats: relevance to sporadic Parkinson’s disease. Environ. Toxicol. [Epub ahead of print].

    Not in our library10.1002/tox.21943

  8. 8.

    Berg J. Roch M. Altschüler J. Winter C. Schwerk A. Kurtz A. (2014 ). Human adipose-derived mesenchymal stem cells improve motor functions and are neuroprotective in the 6-hydroxydopamine-rat model for parkinson’s disease when cultured in monolayer cultures but suppress hippocampal neurogenesis and hippocampal memory functi. Stem Cell Rev. Rep. [Epub ahead of print].

    Not in our library10.1007/s12015-014-9551-y

  9. 9.

    Berry C. La Vecchia C. Nicotera P. (2010 ). Paraquat and Parkinson’s disease. Cell Death Differ. 17 1115–1125

    Not in our library10.1038/cdd.2009.217

  10. 10.

    Betarbet R. Sherer T. B. MacKenzie G. Garcia-Osuna M. Panov A. V. Greenamyre J. T. (2000 ). Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat. Neurosci. 3 1301–1306

    Not in our library10.1038/81834

  11. 11.

    Bezard E. Imbert C. Deloire X. Bioulac B. Gross C. E. (1997 ). A chronic MPTP model reproducing the slow evolution of Parkinson’s disease: evolution of motor symptoms in the monkey. Brain Res. 766 107–112

    Not in our library10.1016/s0006-8993(97)00531-3

  12. 12.

    Blandini F. Armentero M.-T. Martignoni E. (2008 ). The 6-hydroxydopamine model: news from the past. Parkinsonism Relat. Disord. 14(Suppl. 2), S124–S129

    Not in our library10.1016/j.parkreldis.2008.04.015

  13. 13.

    Blesa J. Juri C. Collantes M. Peñuelas I. Prieto E. Iglesias E. (2010 ). Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study. Neurobiol. Dis. 38 456–463

    Not in our library10.1016/j.nbd.2010.03.006

  14. 14.
    Inter-hemispheric asymmetry of nigrostriatal dopaminergic lesion. A possible compensatory mechanism in Parkinson’s disease · 2011
    Not checked
  15. 15.

    Blesa J. Pifl C. Sánchez-González M. A. Juri C. García-Cabezas M. A. Adánez R. (2012 ). The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study. Neurobiol. Dis. 48 79–91

    Not in our library10.1016/j.nbd.2012.05.018

  16. 16.

    Brehm N. Bez F. Carlsson T. Kern B. Gispert S. Auburger G. (2014 ). A genetic mouse model of Parkinson’s disease shows involuntary movements and increased postsynaptic sensitivity to apomorphine. Mol. Neurobiol. [Epub ahead of print].

    Not in our library10.1007/s12035-014-8911-8916

  17. 17.

    Brichta L. Greengard P. Flajolet M. (2013 ). Advances in the pharmacological treatment of Parkinson’s disease: targeting neurotransmitter systems. Trends Neurosci. 36 543–554

    Not in our library10.1016/j.tins.2013.06.003

  18. 18.

    Brooks A. I. Chadwick C. A. Gelbard H. A. Cory-Slechta D. A. Federoff H. J. (1999 ). Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res. 823 1–10

    Not in our library10.1016/s0006-8993(98)01192-5

  19. 19.

    Cadet J. L. Krasnova I. N. Jayanthi S. Lyles J. (2007 ). Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox. Res. 11 183–202

    Not in our library10.1007/bf03033567

  20. 20.
    Rodent models of Parkinson's disease: beyond the motor symptomatology · 2013
    No notice
  21. 21.

    Cannon J. R. Tapias V. Na H. M. Honick A. S. Drolet R. E. Greenamyre J. T. (2009 ). A highly reproducible rotenone model of Parkinson’s disease. Neurobiol. Dis. 34 279–290.

    Not in our library10.1016/j.nbd.2009.01.016

  22. 22.

    Capela J. P. Carmo H. Remião F. Bastos M. L. Meisel A. Carvalho F. (2009 ). Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol. Neurobiol. 39 210–271

    Not in our library10.1007/s12035-009-8064-8061

  23. 23.

    Chege P. M. McColl G. (2014 ). Caenorhabditis elegans: a model to investigate oxidative stress and metal dyshomeostasis in Parkinson’s disease. Front. Aging Neurosci. 6:89

    Not in our library10.3389/fnagi.2014.00089

  24. 24.

    Chen C.-Y. Weng Y.-H. Chien K.-Y. Lin K.-J. Yeh T.-H. Cheng Y.-P. (2012 ). (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. Cell Death Differ. 19 1623–1633

    Not in our library10.1038/cdd.2012.42

  25. 25.

    Chen L. Thiruchelvam M. J. Madura K. Richfield E. K. (2006 ). Proteasome dysfunction in aged human alpha-synuclein transgenic mice. Neurobiol. Dis. 23 120–126

    Not in our library10.1016/j.nbd.2006.02.004

  26. 26.

    Chiueh C. C. Markey S. P. Burns R. S. Johannessen J. N. Jacobowitz D. M. Kopin I. J. (1984 ). Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. Psychopharmacol. Bull. 20 548–553.

    Not in our library

  27. 27.

    Costa G. Frau L. Wardas J. Pinna A. Plumitallo A. Morelli M. (2013 ). MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice. Mov. Disord. 28 1957–1965

    Not in our library10.1002/mds.25646

  28. 28.
    The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution · 2014
    No notice
  29. 29.

    Dauer W. Kholodilov N. Vila M. Trillat A.-C. C. Goodchild R. Larsen K. E. (2002 ). Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U.S.A. 99 14524–14529

    Not in our library10.1073/pnas.172514599

  30. 30.

    Dauer W. Przedborski S. (2003 ). Parkinson’s disease: mechanisms and models. Neuron 39 889–909

    Not in our library10.1016/s0896-6273(03)00568-3

  31. 31.

    Dawson T. M. Ko H. S. Dawson V. L. (2010 ). Genetic animal models of Parkinson’s disease. Neuron 66 646–661

    Not in our library10.1016/j.neuron.2010.04.034

  32. 32.

    Day B. J. Patel M. Calavetta L. Chang L. Y. Stamler J. S. (1999 ). A mechanism of paraquat toxicity involving nitric oxide synthase. Proc. Natl. Acad. Sci. U.S.A. 96 12760–12765

    Not in our library10.1073/pnas.96.22.12760

  33. 33.
    Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons · 2012
    Not checked
  34. 34.

    Dong Z. Ferger B. Feldon J. Büeler H. (2002 ). Overexpression of Parkinson’s disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. J. Neurobiol. 53 1–10

    Not in our library10.1002/neu.10094

  35. 35.

    Drui G. Carnicella S. Carcenac C. Favier M. Bertrand A. Boulet S. (2014 ). Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson’s disease. Mol. Psychiatry 19 358–367

    Not in our library10.1038/mp.2013.3

  36. 36.

    Dunnett S. B. Lelos M. (2010 ). Behavioral analysis of motor and non-motor symptoms in rodent models of Parkinson’s disease. Prog. Brain Res. 184 35–51

    Not in our library10.1016/s0079-6123(10)840038

  37. 37.

    Dusonchet J. Kochubey O. Stafa K. Young S. M. Zufferey R. Moore D. J. (2011 ). A rat model of progressive nigral neurodegeneration induced by the Parkinson’s disease-associated G2019S mutation in LRRK2. J. Neurosci. 31 907–912

    Not in our library10.1523/jneurosci.5092-10.2011

  38. 38.

    Ekstrand M. I. Terzioglu M. Galter D. Zhu S. Hofstetter C. Lindqvist E. (2007 ). Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc. Natl. Acad. Sci. U.S.A. 104 1325–1330

    Not in our library10.1073/pnas.0605208103

  39. 39.
    Low concentrations of methamphetamine can protect dopaminergic cells against a larger oxidative stress injury: mechanistic study. · 2011
    Not checked
  40. 40.

    Exner N. Lutz A. K. Haass C. Winklhofer K. F. (2012 ). Mitochondrial dysfunction in Parkinson’s disease: molecular mechanisms and pathophysiological consequences. EMBO J. 31 3038–3062

    Not in our library10.1038/emboj.2012.170

  41. 41.

    Fleming S. M. Zhu C. Fernagut P.-O. Mehta A. DiCarlo C. D. Seaman R. L. (2004 ). Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp. Neurol. 187 418–429

    Not in our library10.1016/j.expneurol.2004.01.023

  42. 42.

    Forno L. S. Langston J. W. DeLanney L. E. Irwin I. Ricaurte G. A. (1986 ). Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann. Neurol. 20 449–455

    Not in our library10.1002/ana.410200403

  43. 43.

    Freire C. Koifman S. (2012 ). Pesticide exposure and Parkinson’s disease: epidemiological evidence of association. Neurotoxicology 33 947–971

    Not in our library10.1016/j.neuro.2012.05.011

  44. 44.

    Friedman L. G. Lachenmayer M. L. Wang J. He L. Poulose S. M. Komatsu M. (2012 ). Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of α-synuclein and LRRK2 in the brain. J. Neurosci. 32 7585–7593

    Not in our library10.1523/jneurosci.5809-11.2012

  45. 45.
    PINK1-Associated Parkinson's Disease Is Caused by Neuronal Vulnerability to Calcium-Induced Cell Death · 2009
    No notice
  46. 46.

    Gautier C. A. Kitada T. Shen J. (2008 ). Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 105 11364–11369

    Not in our library10.1073/pnas.0802076105

  47. 47.

    Giasson B. I. Duda J. E. Quinn S. M. Zhang B. Trojanowski J. Q. Lee V. M. (2002 ). Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34 521–533

    Not in our library10.1016/s0896-6273(02)00682-7

  48. 48.

    Gispert S. Del Turco D. Garrett L. Chen A. Bernard D. J. Hamm-Clement J. (2003 ). Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol. Cell. Neurosci. 24 419–429

    Not in our library10.1016/s1044-7431(03)00198-2

  49. 49.
    Parkinson Phenotype in Aged PINK1-Deficient Mice Is Accompanied by Progressive Mitochondrial Dysfunction in Absence of Neurodegeneration · 2009
    No notice
  50. 50.

    Glajch K. E. Fleming S. M. Surmeier D. J. Osten P. (2012 ). Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson’s disease. Behav. Brain Res. 230 309–316

    Not in our library10.1016/j.bbr.2011.12.007

  51. 51.

    Goedert M. Spillantini M. G. Del Tredici K. Braak H. (2013 ). 100 years of Lewy pathology. Nat. Rev. Neurol. 9 13–24

    Not in our library10.1038/nrneurol.2012.242

  52. 52.

    Goldberg M. S. Fleming S. M. Palacino J. J. Cepeda C. Lam H. A. Bhatnagar A. (2003 ). Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 278 43628–43635

    Not in our library10.1074/jbc.m308947200

  53. 53.

    Goldberg M. S. Pisani A. Haburcak M. Vortherms T. A. Kitada T. Costa C. (2005 ). Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45 489–496

    Not in our library10.1016/j.neuron.2005.01.041

  54. 54.

    Gomez-Isla T. Irizarry M. C. Mariash A. Cheung B. Soto O. Schrump S. (2003 ). Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol. Aging 24 245–258

    Not in our library10.1016/s0197-4580(02)00091-x

  55. 55.

    Gonzalez-Reyes L. E. Verbitsky M. Blesa J. Jackson-Lewis V. Paredes D. Tillack K. (2012 ). Sonic hedgehog maintains cellular and neurochemical homeostasis in the adult nigrostriatal circuit. Neuron 75 306–319

    Not in our library10.1016/j.neuron.2012.05.018

  56. 56.

    Good C. H. Hoffman A. F. Hoffer B. J. Chefer V. I. Shippenberg T. S. Bäckman C. M. (2011 ). Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson’s disease. FASEB J. 25 1333–1344

    Not in our library10.1096/fj.10-173625

  57. 57.

    Granado N. Escobedo I. O’Shea E. Colado I. Moratalla R. (2008a ). Early loss of dopaminergic terminals in striosomes after MDMA administration to mice. Synapse 62 80–84

    Not in our library10.1002/syn.20466

  58. 58.

    Granado N. O’Shea E. Bove J. Vila M. Colado M. I. Moratalla R. (2008b ). Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice. J. Neurochem. 107 1102–1112

    Not in our library10.1111/j.1471-4159.2008.05705.x

  59. 59.

    Guo M. (2012 ). Drosophila as a model to study mitochondrial dysfunction in Parkinson’s disease. Cold Spring Harb. Perspect. Med. 2 pii:a009944.

    Not in our library10.1101/cshperspect.a009944

  60. 60.

    Halliday G. Herrero M. T. Murphy K. McCann H. Ros-Bernal F. Barcia C. (2009 ). No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism. Mov. Disord. 24 1519–1523

    Not in our library10.1002/mds.22481

  61. 61.

    Haque M. E. Mount M. P. Safarpour F. Abdel-Messih E. Callaghan S. Mazerolle C. (2012 ). Inactivation of Pink1 gene in vivo sensitizes dopamine-producing neurons to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and can be rescued by autosomal recessive Parkinson disease genes, Parkin or DJ-1. J. Biol. Chem. 287 23162–23170

    Not in our library10.1074/jbc.m112.346437

  62. 62.
    Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study · 2008
    No notice
  63. 63.

    Heinzen E. L. Arzimanoglou A. Brashear A. Clapcote S. J. Gurrieri F. Goldstein D. B. (2014 ). Distinct neurological disorders with ATP1A3 mutations. Lancet. Neurol. 13 503–514

    Not in our library10.1016/s1474-4422(14)70011-70010

  64. 64.

    Hennis M. R. Marvin M. A. Taylor C. M. Goldberg M. S. (2014 ). Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson’s disease. Neurobiol. Dis. 62 113–123

    Not in our library10.1016/j.nbd.2013.09.009

  65. 65.

    Hennis M. R. Seamans K. W. Marvin M. A. Casey B. H. Goldberg M. S. (2013 ). Behavioral and neurotransmitter abnormalities in mice deficient for Parkin, DJ-1 and superoxide dismutase. PLoS ONE 8:e84894

    Not in our library10.1371/journal.pone.0084894

  66. 66.

    Herzig M. C. Kolly C. Persohn E. Theil D. Schweizer T. Hafner T. (2011 ). LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum. Mol. Genet. 20 4209–4223

    Not in our library10.1093/hmg/ddr348

  67. 67.

    Hess A. Desiderio C. McAuliffe W. G. (1990 ). Acute neuropathological changes in the caudate nucleus caused by MPTP and methamphetamine: immunohistochemical studies. J. Neurocytol. 19 338–342

    Not in our library10.1007/bf01188403

  68. 68.
    LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors · 2012
    No notice
  69. 69.

    Howard C. D. Keefe K. A. Garris P. A. Daberkow D. P. (2011 ). Methamphetamine neurotoxicity decreases phasic, but not tonic, dopaminergic signaling in the rat striatum. J. Neurochem. 118 668–676

    Not in our library10.1111/j.1471-4159.2011.07342.x

  70. 70.

    Hwang D.-Y. Ardayfio P. Kang U. J. Semina E. V Kim K.-S. (2003 ). Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res. Mol. Brain Res. 114 123–131

    Not in our library10.1016/s0169-328x(03)00162-1

  71. 71.

    Ikeda M. Kawarabayashi T. Harigaya Y. Sasaki A. Yamada S. Matsubara E. (2009 ). Motor impairment and aberrant production of neurochemicals in human alpha-synuclein A30P+A53T transgenic mice with alpha-synuclein pathology. Brain Res. 1250 232–241

    Not in our library10.1016/j.brainres.2008.10.011

  72. 72.

    Itier J.-M. Ibanez P. Mena M. A. Abbas N. Cohen-Salmon C. Bohme G. A. (2003 ). Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum. Mol. Genet. 12 2277–2291

    Not in our library10.1093/hmg/ddg239

  73. 73.

    Jackson-Lewis V. Przedborski S. (2007 ). Protocol for the MPTP mouse model of Parkinson’s disease. Nat. Protoc. 2 141–151

    Not in our library10.1038/nprot.2006.342

  74. 74.

    Janezic S. Threlfell S. Dodson P. D. Dowie M. J. Taylor T. N. Potgieter D. (2013 ). Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc. Natl. Acad. Sci. U.S.A. 110 E4016–E4025

    Not in our library10.1073/pnas.1309143110

  75. 75.

    Jankovic J. Chen S. Le W. D. (2005 ). The role of Nurr1 in the development of dopaminergic neurons and Parkinson’s disease. Prog. Neurobiol. 77 128–138

    Not in our library10.1016/j.pneurobio.2005.09.001

  76. 76.

    Jensen K. F. Olin J. Haykal-Coates N. O’Callaghan J. Miller D. B. de Olmos J. S. (1993 ). Mapping toxicant-induced nervous system damage with a cupric silver stain: a quantitative analysis of neural degeneration induced by 3,4-methylenedioxymethamphetamine. NIDA Res. Monogr. 136 133–149; discussion 150–154.

    Not in our library10.1037/e495922006-008

  77. 77.

    Jiang C. Wan X. He Y. Pan T. Jankovic J. Le W. (2005 ). Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp. Neurol. 191 154–162

    Not in our library10.1016/j.expneurol.2004.08.035

  78. 78.

    Joselin A. P. Hewitt S. J. Callaghan S. M. Kim R. H. Chung Y.-H. Mak T. W. (2012 ). ROS-dependent regulation of Parkin and DJ-1 localization during oxidative stress in neurons. Hum. Mol. Genet. 21 4888–4903

    Not in our library10.1093/hmg/dds325

  79. 79.

    Kadkhodaei B. Ito T. Joodmardi E. Mattsson B. Rouillard C. Carta M. (2009 ). Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J. Neurosci. 29 15923–15932

    Not in our library10.1523/jneurosci.3910-09.2009

  80. 80.

    Kara E. Kiely A. P. Proukakis C. Giffin N. Love S. Hehir J. (2014 ). A 6.4 Mb duplication of the α-synuclein locus causing frontotemporal dementia and parkinsonism: phenotype-genotype correlations. JAMA Neurol. 71 1162–1171

    Not in our library10.1001/jamaneurol.2014.994

  81. 81.

    Kim R. H. Smith P. D. Aleyasin H. Hayley S. Mount M. P. Pownall S. (2005 ). Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 102 5215–5220

    Not in our library10.1073/pnas.0501282102

  82. 82.

    Kirik D. Annett L. E. Burger C. Muzyczka N. Mandel R. J. Björklund A. (2003 ). Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson’s disease. Proc. Natl. Acad. Sci. U.S.A. 100 2884–2889

    Not in our library10.1073/pnas.0536383100

  83. 83.

    Kirik D. Rosenblad C. Burger C. Lundberg C. Johansen T. E. Muzyczka N. (2002 ). Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22 2780–2791.

    Not in our library10.1523/jneurosci.22-07-02780.2002

  84. 84.

    Kitada T. Pisani A. Karouani M. Haburcak M. Martella G. Tscherter A. (2009a ). Impaired dopamine release and synaptic plasticity in the striatum of parkin-/- mice. J. Neurochem. 110 613–621

    Not in our library10.1111/j.1471-4159.2009.06152.x

  85. 85.

    Kitada T. Tong Y. Gautier C. A. Shen J. (2009b ). Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice. J. Neurochem. 111 696–702

    Not in our library10.1111/j.1471-4159.2009.06350.x

  86. 86.

    Klein R. L. King M. A. Hamby M. E. Meyer E. M. (2002 ). Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum. Gene Ther. 13 605–612

    Not in our library10.1089/10430340252837206

  87. 87.

    Kogan F. J. Nichols W. K. Gibb J. W. (1976 ). Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur. J. Pharmacol. 36 363–371

    Not in our library10.1016/0014-2999(76)90090-x

  88. 88.

    Kowall N. W. Hantraye P. Brouillet E. Beal M. F. McKee A. C. Ferrante R. J. (2000 ). MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11 211–213.

    Not in our library10.1097/00001756-200001170-00041

  89. 89.

    Lachenmayer M. L. Yue Z. (2012 ). Genetic animal models for evaluating the role of autophagy in etiopathogenesis of Parkinson disease. Autophagy 8 1837–1838

    Not in our library10.4161/auto.21859

  90. 90.

    Lam H. A. Wu N. Cely I. Kelly R. L. Hean S. Richter F. (2011 ). Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein. J. Neurosci. Res. 89 1091–1102

    Not in our library10.1002/jnr.22611

  91. 91.

    Langston J. W. Ballard P. Tetrud J. W. Irwin I. (1983 ). Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 979–980

    Not in our library10.1126/science.6823561

  92. 92.

    Lauwers E. Bequé D. Van Laere K. Nuyts J. Bormans G. Mortelmans L. (2007 ). Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression. Neurobiol. Aging 28 248–257

    Not in our library10.1016/j.neurobiolaging.2005.12.005

  93. 93.

    Lauwers E. Debyser Z. Van Dorpe J. De Strooper B. Nuttin B. Baekelandt V. (2003 ). Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol. 13 364–372

    Not in our library10.1111/j.1750-3639.2003.tb00035.x

  94. 94.

    Lee B. D. Shin J.-H. VanKampen J. Petrucelli L. West A. B. Ko H. S. (2010 ). Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson’s disease. Nat. Med. 16 998–1000

    Not in our library10.1038/nm.2199

  95. 95.

    Li J. Dani J. A. Le W. (2009a ). The role of transcription factor Pitx3 in dopamine neuron development and Parkinson’s disease. Curr. Top. Med. Chem. 9 855–859.

    Not in our library

  96. 96.

    Li Y. Liu W. Oo T. F. Wang L. Tang Y. Jackson-Lewis V. (2009b ). Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson’s disease. Nat. Neurosci. 12 826–828

    Not in our library10.1038/nn.2349

  97. 97.

    Li X. Patel J. C. Wang J. Avshalumov M. V. Nicholson C. Buxbaum J. D. (2010 ). Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson’s disease mutation G2019S. J. Neurosci. 30 1788–1797

    Not in our library10.1523/jneurosci.5604-09.2010

  98. 98.

    Lin X. Parisiadou L. Gu X.-L. Wang L. Shim H. Sun L. (2009 ). Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson’s-disease-related mutant alpha-synuclein. Neuron 64 807–827

    Not in our library10.1016/j.neuron.2009.11.006

  99. 99.

    Lin X. Parisiadou L. Sgobio C. Liu G. Yu J. Sun L. (2012 ). Conditional expression of Parkinson’s disease-related mutant α-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. J. Neurosci. 32 9248–9264

    Not in our library10.1523/jneurosci.1731-12.2012

  100. 100.

    Lo Bianco C. Ridet J.-L. Schneider B. L. Deglon N. Aebischer P. (2002 ). alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson’s disease. Proc. Natl. Acad. Sci. U.S.A. 99 10813–10818

    Not in our library10.1073/pnas.152339799

  101. 101.

    Lohr K. M. Bernstein A. I. Stout K. A. Dunn A. R. Lazo C. R. Alter S. P. (2014 ). Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proc. Natl. Acad. Sci. U.S.A. 111 9977–9982

    Not in our library10.1073/pnas.1402134111

  102. 102.

    Lu X.-H. Fleming S. M. Meurers B. Ackerson L. C. Mortazavi F. Lo V. (2009 ). Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein. J. Neurosci. 29 1962–1976

    Not in our library10.1523/jneurosci.5351-08.2009

  103. 103.

    Lücking C. B. Dürr A. Bonifati V. Vaughan J. De Michele G. Gasser T. (2000 ). Association between early-onset Parkinson’s disease and mutations in the parkin gene. N. Engl. J. Med. 342 1560–1567

    Not in our library10.1056/nejm200005253422103

  104. 104.

    Luk K. C. Kehm V. Carroll J. Zhang B. O’Brien P. Trojanowski J. Q. (2012a ). Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338 949–953

    Not in our library10.1126/science.1227157

  105. 105.

    Luk K. C. Kehm V. M. Zhang B. O’Brien P. Trojanowski J. Q. Lee V. M. Y. (2012b ). Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J. Exp. Med. 209 975–986

    Not in our library10.1084/jem.20112457

  106. 106.

    Luk K. C. Lee V. M.-Y. (2014 ). Modeling Lewy pathology propagation in Parkinson’s disease. Parkinsonism Relat. Disord. 20(Suppl. 1), S85–S87

    Not in our library10.1016/s1353-8020(13)70022-70021

  107. 107.

    Maekawa T. Mori S. Sasaki Y. Miyajima T. Azuma S. Ohta E. (2012 ). The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities. Mol. Neurodegener. 7 15

    Not in our library10.1186/1750-1326-715

  108. 108.

    Manning-Bog A. B. McCormack A. L. Li J. Uversky V. N. Fink A. L. Di Monte D. A. (2002 ). The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 277 1641–1644

    Not in our library10.1074/jbc.c100560200

  109. 109.

    Martella G. Platania P. Vita D. Sciamanna G. Cuomo D. Tassone A. (2009 ). Enhanced sensitivity to group II mGlu receptor activation at corticostriatal synapses in mice lacking the familial parkinsonism-linked genes PINK1 or Parkin. Exp. Neurol. 215 388–396

    Not in our library10.1016/j.expneurol.2008.11.001

  110. 110.

    Masliah E. Rockenstein E. Veinbergs I. Mallory M. Hashimoto M. Takeda A. (2000 ). Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287 1265–1269

    Not in our library10.1126/science.287.5456.1265

  111. 111.

    Masuda-Suzukake M. Nonaka T. Hosokawa M. Kubo M. Shimozawa A. Akiyama H. (2014 ). Pathological alpha-synuclein propagates through neural networks. Acta Neuropathol. Commun. 2 88

    Not in our library10.1186/preaccept-1296467154135944

  112. 112.

    Matsui H. Uemura N. Yamakado H. Takeda S. Takahashi R. (2014 ). Exploring the pathogenetic mechanisms underlying Parkinson’s disease in medaka fish. J. Parkinsons. Dis. 4 301–310

    Not in our library10.3233/jpd-130289

  113. 113.

    Matsuoka Y. Vila M. Lincoln S. McCormack A. Picciano M. LaFrancois J. (2001 ). Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8 535–539

    Not in our library10.1006/nbdi.2001.0392

  114. 114.

    McCormack A. L. Thiruchelvam M. Manning-Bog A. B. Thiffault C. Langston J. W. Cory-Slechta D. A. (2002 ). Environmental risk factors and Parkinson’s disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 10 119–127

    Not in our library10.1006/nbdi.2002.0507

  115. 115.

    McDowell K. Chesselet M.-F. (2012 ). Animal models of the non-motor features of Parkinson’s disease. Neurobiol. Dis. 46 597–606

    Not in our library10.1016/j.nbd.2011.12.040

  116. 116.

    Melrose H. L. Dächsel J. C. Behrouz B. Lincoln S. J. Yue M. Hinkle K. M. (2010 ). Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol. Dis. 40 503–517

    Not in our library10.1016/j.nbd.2010.07.010

  117. 117.

    Meredith G. E. Totterdell S. Potashkin J. A. Surmeier D. J. (2008 ). Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Park. Relat Disord 14(Suppl. 2), S112–S115

    Not in our library10.1016/j.parkreldis.2008.04.012

  118. 118.

    Miller G. W. (2007 ). Paraquat: the red herring of Parkinson’s disease research. Toxicol. Sci. 100 1–2

    Not in our library10.1093/toxsci/kfm223

  119. 119.

    Miller R. M. Kiser G. L. Kaysser-Kranich T. Casaceli C. Colla E. Lee M. K. (2007 ). Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD. Exp. Neurol. 204 421–432

    Not in our library10.1016/j.expneurol.2006.12.005

  120. 120.

    Morais V. A. Haddad D. Craessaerts K. De Bock P.-J. Swerts J. Vilain S. (2014 ). PINK1 loss-of-function mutations affect mitochondrial complex I activity via NdufA10 ubiquinone uncoupling. Science 344 203–207

    Not in our library10.1126/science.1249161

  121. 121.

    Moratalla R. Quinn B. DeLanney L. E. Irwin I. Langston J. W. Graybiel A. M. (1992 ). Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U.S.A. 89 3859–3863

    Not in our library10.1073/pnas.89.9.3859

  122. 122.

    Morin N. Jourdain V. A. Di Paolo T. (2014 ). Modeling dyskinesia in animal models of Parkinson disease. Exp. Neurol. 256 105–116

    Not in our library10.1016/j.expneurol.2013.01.024

  123. 123.

    Morrow B. A. Roth R. H. Redmond D. E. Elsworth J. D. (2011 ). Impact of methamphetamine on dopamine neurons in primates is dependent on age: implications for development of Parkinson’s disease. Neuroscience 189 277–285

    Not in our library10.1016/j.neuroscience.2011.05.046

  124. 124.

    Muthane U. Ramsay K. A. Jiang H. Jackson-Lewis V. Donaldson D. Fernando S. (1994 ). Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Exp. Neurol. 126 195–204

    Not in our library10.1006/exnr.1994.1058

  125. 125.
    Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis. · 2013
    Not checked
  126. 126.

    Nieto M. Gil-Bea F. J. Dalfó E. Cuadrado M. Cabodevilla F. Sánchez B. (2006 ). Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice. Neurobiol. Aging 27 848–856

    Not in our library10.1016/j.neurobiolaging.2005.04.010

  127. 127.
    Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease · 2015
    Not checked
  128. 128.

    Oaks A. W. Frankfurt M. Finkelstein D. I. Sidhu A. (2013 ). Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function. PLoS ONE 8:e60378

    Not in our library10.1371/journal.pone.0060378

  129. 129.

    Obeso J. A. Rodriguez-Oroz M. C. Stamelou M. Bhatia K. P. Burn D. J. (2014 ). The expanding universe of disorders of the basal ganglia. Lancet 384 523–531

    Not in our library10.1016/s0140-6736(13)62418-62416

  130. 130.

    O’Callaghan J. P. Miller D. B. (1994 ). Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270 741–751.

    Not in our library

  131. 131.

    Oliveras-Salvá M. Macchi F. Coessens V. Deleersnijder A. Gérard M. Van der Perren A. (2014 ). Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice. Neurobiol. Aging 35 2625–2636

    Not in our library10.1016/j.neurobiolaging.2014.04.032

  132. 132.
    rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration · 2013
    No notice
  133. 133.

    Ono K. Ikemoto M. Kawarabayashi T. Ikeda M. Nishinakagawa T. Hosokawa M. (2009 ). A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice. Parkinsonism Relat. Disord. 15 649–654

    Not in our library10.1016/j.parkreldis.2009.03.002

  134. 134.

    Ottolini D. Calì T. Negro A. Brini M. (2013 ). The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering. Hum. Mol. Genet. 22 2152–2168

    Not in our library10.1093/hmg/ddt068

  135. 135.

    Palacino J. J. Sagi D. Goldberg M. S. Krauss S. Motz C. Wacker M. (2004 ). Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 279 18614–18622

    Not in our library10.1074/jbc.m401135200

  136. 136.
    Progression of Parkinson's Disease Pathology Is Reproduced by Intragastric Administration of Rotenone in Mice · 2010
    No notice
  137. 137.
    Behavioral Characterization of A53T Mice Reveals Early and Late Stage Deficits Related to Parkinson’s Disease · 2013
    No notice
  138. 138.

    Perez F. A. Palmiter R. D. (2005 ). Parkin-deficient mice are not a robust model of parkinsonism. Proc. Natl. Acad. Sci. U.S.A. 102 2174–2179

    Not in our library10.1073/pnas.0409598102

  139. 139.

    Periquet M. Latouche M. Lohmann E. Rawal N. De Michele G. Ricard S. (2003 ). Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain 126 1271–1278

    Not in our library10.1093/brain/awg136

  140. 140.

    Pham T. T. Giesert F. Röthig A. Floss T. Kallnik M. Weindl K. (2010 ). DJ-1-deficient mice show less TH-positive neurons in the ventral tegmental area and exhibit non-motoric behavioural impairments. Genes Brain Behav. 9 305–317

    Not in our library10.1111/j.1601-183x.2009.00559.x

  141. 141.

    Pifl C. Rajput A. Reither H. Blesa J. Cavada C. Obeso J. A (2014 ). Is Parkinson’s disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum. J. Neurosci. 34 8210–8218

    Not in our library10.1523/jneurosci.5456-13.2014

  142. 142.

    Porras G. Li Q. Bezard E. (2012 ). Modeling Parkinson’s disease in primates: the MPTP model. Cold Spring Harb. Perspect. Med. 2 a009308

    Not in our library10.1101/cshperspect.a009308

  143. 143.

    Pringsheim T. Jette N. Frolkis A. Steeves T. D. L. (2014 ). The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov. Disord. 29 1583–1590

    Not in our library10.1002/mds.25945

  144. 144.

    Przedborski S. Levivier M. Jiang H. Ferreira M. Jackson-Lewis V. Donaldson D. (1995 ). Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67 631–647

    Not in our library10.1016/0306-4522(95)00066-r

  145. 145.

    Purisai M. G. McCormack A. L. Langston W. J. Johnston L. C. Di Monte D. A. (2005 ). Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol. Dis. 20 898–906

    Not in our library10.1016/j.nbd.2005.05.028

  146. 146.

    Puschmann A. (2013 ). Monogenic Parkinson’s disease and parkinsonism: clinical phenotypes and frequencies of known mutations. Parkinsonism Relat. Disord. 19 407–415

    Not in our library10.1016/j.parkreldis.2013.01.020

  147. 147.
    Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2 · 2011
    No notice
  148. 148.

    Rappold P. M. Cui M. Chesser A. S. Tibbett J. Grima J. C. Duan L. (2011 ). Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3. Proc. Natl. Acad. Sci. U.S.A. 108 20766–20771

    Not in our library10.1073/pnas.1115141108

  149. 149.

    Rathke-Hartlieb S. Kahle P. J. Neumann M. Ozmen L. Haid S. Okochi M. (2001 ). Sensitivity to MPTP is not increased in Parkinson’s disease-associated mutant alpha-synuclein transgenic mice. J. Neurochem. 77 1181–1184

    Not in our library10.1046/j.1471-4159.2001.00366.x

  150. 150.

    Recasens A. Dehay B. Bové J. Carballo-Carbajal I. Dovero S. Pérez-Villalba A. (2014 ). Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol. 75 351–362

    Not in our library10.1002/ana.24066

  151. 151.

    Rockenstein E. Mallory M. Hashimoto M. Song D. Shults C. W. Lang I. (2002 ). Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res. 68 568–578

    Not in our library10.1002/jnr.10231

  152. 152.

    Rodríguez Díaz M. Abdala P. Barroso-Chinea P. Obeso J. Gonzalez-Hernandez T. (2001 ). Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson’s disease. Behav. Brain Res. 122 79–92

    Not in our library10.1016/s0166-4328(01)00168-1

  153. 153.

    Rodriguez-Oroz M. C. Jahanshahi M. Krack P. Litvan I. Macias R. Bezard E. (2009 ). Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms. Lancet Neurol. 8 1128–1139

    Not in our library10.1016/s1474-4422(0970293-70295

  154. 154.

    Rousseaux M. W. C. Marcogliese P. C. Qu D. Hewitt S. J. Seang S. Kim R. H. (2012 ). Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 109 15918–15923

    Not in our library10.1073/pnas.1205102109

  155. 155.

    Rudenko I. N. Cookson M. R. (2014 ). Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications. Neurotherapeutics 4 738–750

    Not in our library10.1007/s13311-014-0284-z

  156. 156.

    Sacino A. N. Brooks M. Thomas M. A. McKinney A. B. Lee S. Regenhardt R. W. (2014 ). Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 111 10732–10737

    Not in our library10.1073/pnas.1321785111

  157. 157.

    Sanchez G. Varaschin R. K. Büeler H. Marcogliese P. C. Park D. S. Trudeau L.-E. (2014 ). Unaltered striatal dopamine release levels in young Parkin knockout, Pink1 knockout, DJ-1 knockout and LRRK2 R1441G transgenic mice. PLoS ONE 9:e94826

    Not in our library10.1371/journal.pone.0094826

  158. 158.

    Sauer H. Oertel W. H. (1994 ). Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59 401–415

    Not in our library10.1016/0306-4522(94)90605-x

  159. 159.

    Scarffe L. A. Stevens D. A. Dawson V. L. Dawson T. M. (2014 ). Parkin and PINK1: much more than mitophagy. Trends Neurosci. 37 315–324

    Not in our library10.1016/j.tins.2014.03.004

  160. 160.

    Schallert T. Fleming S. M. Leasure J. L. Tillerson J. L. Bland S. T. (2000 ). CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39 777–787

    Not in our library10.1016/s0028-3908(00)00005-8

  161. 161.

    Schapira A. H. V. Olanow C. W. Greenamyre J. T. Bezard E. (2014 ). Slowing of neurodegeneration in Parkinson’s disease and Huntington’s disease: future therapeutic perspectives. Lancet 384 545–555

    Not in our library10.1016/s0140-6736(14)61010-61012

  162. 162.

    Schultheis P. J. Fleming S. M. Clippinger A. K. Lewis J. Tsunemi T. Giasson B. (2013 ). Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits. Hum. Mol. Genet. 22 2067–2082

    Not in our library10.1093/hmg/ddt057

  163. 163.

    Seniuk N. A. Tatton W. G. Greenwood C. E. (1990 ). Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res. 527 7–20

    Not in our library10.1016/0006-8993(90)91055-l

  164. 164.

    Sherer T. B. Kim J. H. Betarbet R. Greenamyre J. T. (2003 ). Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 179 9–16

    Not in our library10.1006/exnr.2002.8072

  165. 165.

    Shimoji M. Zhang L. Mandir A. S. Dawson V. L. Dawson T. M. (2005 ). Absence of inclusion body formation in the MPTP mouse model of Parkinson’s disease. Brain Res. Mol. Brain Res. 134 103–108

    Not in our library10.1016/j.molbrainres.2005.01.012

  166. 166.

    Singleton A. B. Farrer M. Johnson J. Singleton A. Hague S. Kachergus J. (2003 ). alpha-Synuclein locus triplication causes Parkinson’s disease. Science 302 841

    Not in our library10.1126/science.1090278

  167. 167.

    Snow B. J. Vingerhoets F. J. Langston J. W. Tetrud J. W. Sossi V. Calne D. B. (2000 ). Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J. Neurol. Neurosurg. Psychiatry 68 313–316

    Not in our library10.1136/jnnp.68.3.313

  168. 168.

    Sonsalla P. K. Jochnowitz N. D. Zeevalk G. D. Oostveen J. A. Hall E. D. (1996 ). Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res. 738 172–175

    Not in our library10.1016/0006-8993(96)00995-x

  169. 169.

    Sotiriou E. Vassilatis D. K. Vila M. Stefanis L. (2010 ). Selective noradrenergic vulnerability in α-synuclein transgenic mice. Neurobiol. Aging 31 2103–2114

    Not in our library10.1016/j.neurobiolaging.2008.11.010

  170. 170.

    Su X. Federoff H. J. Maguire-Zeiss K. A. (2009 ). Mutant alpha-synuclein overexpression mediates early proinflammatory activity. Neurotox. Res. 16 238–254

    Not in our library10.1007/s12640-009-9053-x

  171. 171.

    Sziráki I. Kardos V. Patthy M. Pátfalusi M. Budai G. (1994 ). Methamphetamine protects against MPTP neurotoxicity in C57BL mice. Eur. J. Pharmacol. 251 311–314

    Not in our library10.1016/0014-2999(94)90416-2

  172. 172.

    Takahashi N. Miner L. L. Sora I. Ujike H. Revay R. S. Kostic V. (1997 ). VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl. Acad. Sci. U.S.A. 94 9938–9943.

    Not in our library10.1073/pnas.94.18.9938

  173. 173.

    Takahashi R. N. Rogerio R. Zanin M. (1989 ). Maneb enhances MPTP neurotoxicity in mice. Res. Commun. Chem. Pathol. Pharmacol. 66 167–170.

    Not in our library

  174. 174.

    Taylor T. N. Alter S. P. Wang M. Goldstein D. S. Miller G. W. (2014 ). Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus. Neuropharmacology 76(Pt A), 97–105

    Not in our library10.1016/j.neuropharm.2013.08.033

  175. 175.

    Taylor T. N. Caudle W. M. Miller G. W. (2011 ). VMAT2-deficient mice display nigral and extranigral pathology and motor and nonmotor symptoms of Parkinson’s disease. Parkinsons Dis. 2011 124165

    Not in our library10.4061/2011/124165

  176. 176.

    Taylor T. N. Greene J. G. Miller G. W. (2010 ). Behavioral phenotyping of mouse models of Parkinson’s disease. Behav. Brain Res. 211 1–10

    Not in our library10.1016/j.bbr.2010.03.004

  177. 177.

    Thiruchelvam M. Brockel B. J. Richfield E. K. Baggs R. B. Cory-Slechta D. A. (2000 ). Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson’s disease? Brain Res. 873 225–234

    Not in our library10.1016/s0006-8993(00)02496-3

  178. 178.

    Thiruchelvam M. McCormack A. Richfield E. K. Baggs R. B. Tank A. W. Di Monte D. A. (2003 ). Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson’s disease phenotype. Eur. J. Neurosci. 18 589–600

    Not in our library10.1046/j.1460-9568.2003.02781.x

  179. 179.

    Thiruchelvam M. J. Powers J. M. Cory-Slechta D. A. Richfield E. K. (2004 ). Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. Eur. J. Neurosci. 19 845–854

    Not in our library10.1111/j.0953-816x.2004.03139.x

  180. 180.

    Thrash B. Thiruchelvan K. Ahuja M. Suppiramaniam V. Dhanasekaran M. (2009 ). Methamphetamine-induced neurotoxicity: the road to Parkinson’s disease. Pharmacol. Rep. 61 966–977

    Not in our library10.1016/s1734-1140(09)70158-6

  181. 181.

    Tieu K. (2011 ). A guide to neurotoxic animal models of Parkinson’s disease. Cold Spring Harb. Perspect. Med. 1 a009316.

    Not in our library10.1101/cshperspect.a009316

  182. 182.

    Tong Y. Pisani A. Martella G. Karouani M. Yamaguchi H. Pothos E. N. (2009 ). R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl. Acad. Sci. U.S.A. 106 14622–14627

    Not in our library10.1073/pnas.0906334106

  183. 183.

    Tong Y. Yamaguchi H. Giaime E. Boyle S. Kopan R. Kelleher R. J. (2010 ). Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc. Natl. Acad. Sci. U.S.A. 107 9879–9884

    Not in our library10.1073/pnas.1004676107

  184. 184.

    Trulson M. E. Cannon M. S. Faegg T. S. Raese J. D. (1985 ). Effects of chronic methamphetamine on the nigral-striatal dopamine system in rat brain: tyrosine hydroxylase immunochemistry and quantitative light microscopic studies. Brain Res. Bull. 15 569–577

    Not in our library10.1016/0361-9230(85)90206-90200

  185. 185.

    Tsika E. Kannan M. Foo C. S.-Y. Dikeman D. Glauser L. Gellhaar S. (2014 ). Conditional expression of Parkinson’s disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. Neurobiol. Dis. 71 345–358

    Not in our library10.1016/j.nbd.2014.08.027

  186. 186.

    Ulusoy A. Sahin G. Kirik D. (2010 ). Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats. Proc. Natl. Acad. Sci. U.S.A. 107 13159–13164

    Not in our library10.1073/pnas.1003432107

  187. 187.

    Ungerstedt U. (1968 ). 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 5 107–110

    Not in our library10.1016/0014-2999(68)90164-7

  188. 188.

    van den Munckhof P. Luk K. C. Ste-Marie L. Montgomery J. Blanchet P. J. Sadikot A. F. (2003 ). Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development 130 2535–2542

    Not in our library10.1242/dev.00464

  189. 189.

    van der Putten H. Wiederhold K. H. Probst A. Barbieri S. Mistl C. Danner S. (2000 ). Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20 6021–6029.

    Not in our library10.1523/jneurosci.20-16-06021.2000

  190. 190.

    Van Rompuy A.-S. Lobbestael E. Van der Perren A. Van den Haute C. Baekelandt V. (2014 ). Long-term overexpression of human wild-type and T240R mutant Parkin in rat substantia nigra induces progressive dopaminergic neurodegeneration. J. Neuropathol. Exp. Neurol. 73 159–174

    Not in our library10.1097/nen.0000000000000039

  191. 191.

    Vekrellis K. Xilouri M. Emmanouilidou E. Rideout H. J. Stefanis L. (2011 ). Pathological roles of α-synuclein in neurological disorders. Lancet Neurol. 10 1015–1025

    Not in our library10.1016/s1474-4422(11)70213-70217

  192. 192.

    Vila M. Vukosavic S. Jackson-Lewis V. Neystat M. Jakowec M. Przedborski S. (2000 ). Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74 721–729

    Not in our library10.1046/j.1471-4159.2000.740721.x

  193. 193.

    Vincow E. S. Merrihew G. Thomas R. E. Shulman N. J. Beyer R. P. MacCoss M. J. (2013 ). The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo. Proc. Natl. Acad. Sci. U.S.A. 110 6400–6405

    Not in our library10.1073/pnas.1221132110

  194. 194.

    Von Coelln R. Thomas B. Savitt J. M. Lim K. L. Sasaki M. Hess E. J. (2004 ). Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc. Natl. Acad. Sci. U.S.A. 101 10744–10749

    Not in our library10.1073/pnas.0401297101

  195. 195.

    Wagner G. C. Seiden L. S. Schuster C. R. (1979 ). Methamphetamine-induced changes in brain catecholamines in rats and guinea pigs. Drug Alcohol Depend. 4 435–438

    Not in our library10.1016/0376-8716(79)90076-90070

  196. 196.

    Wakamatsu M. Ishii A. Iwata S. Sakagami J. Ukai Y. Ono M. (2008 ). Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. Neurobiol. Aging 29 574–585

    Not in our library10.1016/j.neurobiolaging.2006.11.017

  197. 197.
    Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice · 2011
    Not checked
  198. 198.

    Xiong N. Huang J. Zhang Z. Zhang Z. Xiong J. Liu X. (2009 ). Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson’s disease. PLoS ONE 4:e7878

    Not in our library10.1371/journal.pone.0007878

  199. 199.

    Yang X. Xu Y. (2014 ). Mutations in the ATP13A2 gene and parkinsonism: a preliminary review. Biomed Res. Int. 2014 371256

    Not in our library10.1155/2014/371256

  200. 200.

    Zhang H. Duan C. Yang H. (2014 ). Defective autophagy in Parkinson’s disease: lessons from genetics. Mol. Neurobiol. [Epub ahead of print].

    Not in our library10.1007/s12035-014-8787-8785

  201. 201.

    Zhang L. Le W. Xie W. Dani J. A. (2012 ). Age-related changes in dopamine signaling in Nurr1 deficient mice as a model of Parkinson’s disease. Neurobiol. Aging 33 1001e7–1001e16.

    Not in our library10.1016/j.neurobiolaging.2011.03.022

  202. 202.

    Zhou H. Huang C. Tong J. Hong W. C. Liu Y.-J. Xia X.-G. (2011 ). Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int. J. Biol. Sci. 7 753–761

    Not in our library10.7150/ijbs.7.753

  203. 203.

    Zhu X.-R. Maskri L. Herold C. Bader V. Stichel C. C. Güntürkün O. (2007 ). Non-motor behavioural impairments in parkin-deficient mice. Eur. J. Neurosci. 26 1902–1911

    Not in our library10.1111/j.1460-9568.2007.05812.x

Cited by papers we hold 14

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.